Search company, investor...

Predict your next investment

ZhenFund company logo
Venture Capital
FINANCE | Investment Firms & Funds
zhenfund.com

See what CB Insights has to offer

Investments

757

Portfolio Exits

37

Funds

16

Partners & Customers

2

About ZhenFund

ZhenFund was established in 2006 by Xu Xiaoping, one of New Oriental's co-founders, with the aim of promoting innovation among young people in China. Just as New Oriental empowered thousands of Chinese students to study abroad, ZhenFund likewise hopes to create a bridge for overseas returnees to pursue entrepreneurship in China, as well as support domestic entrepreneurs with global vision and integrity to realize their entrepreneurial dreams. Prior to November 2011, ZhenFund was an investor in Shiji Jiayuan, Lightinthebox, Jumei.com, and almost eighty other early stage companies in Mainland China. In December 2011, ZhenFund partnered with Sequoia Capital China on "ZhenFund 2.0" to invest 200mm RMB in early-stage Chinese start-ups. Partnering with Sequoia allows ZhenFund to harness more comprehensive resources for portfolio companies including strategic advice, human resources, legal, and financial assistance - helping portfolio companies start smoothly and scale rapidly.

Headquarters Location

Beijing, Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ZhenFund

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find ZhenFund in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

ZhenFund Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ZhenFund Rank

Research containing ZhenFund

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned ZhenFund in 1 CB Insights research brief, most recently on Jun 11, 2020.

Latest ZhenFund News

Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in Oncology

Sep 29, 2022

September 29, 2022 08:00 AM Eastern Daylight Time MENLO PARK, Calif.--( BUSINESS WIRE )-- Meliora Therapeutics , a biotech company pioneering a machine learning-driven platform to decipher oncology drugs’ true mechanisms-of-action, announced today the close of an $11M seed financing round led by HOF Capital and ZhenFund, with participation from Obvious Ventures, Village Global, BrightEdge (the impact investment arm of the American Cancer Society), Pebblebed (fund of Keith Adams, former Chief Architect at Slack), Axial, Olive Capital, and prominent individual investors Michael Polansky (co-founder of Parker Institute for Cancer Immunotherapy and ArsenalBio), Wes Sterman (founding investor for Gilead), and others. Founded in September 2021, Meliora’s computational platform enables researchers to develop a precise understanding of a drug’s true mechanism of action (MOA) based on data and not guesswork. The company aims to improve the current success rate of oncology drugs in development by building the industry’s first atlas of drug mechanisms and their impact on cancer biology through the use of machine learning. The founding team includes David Li, CEO & Co-Founder, Jason Sheltzer, Ph.D., Scientific Co-Founder and Joan Smith, Technical Co-Founder. Out of all the areas of medicine, clinical trials in oncology have the absolute lowest success rate—3%. One reason for the high failure rate is that many cancer drugs in development have an incorrect characterization of their mechanism of action, according to a paper published by Meliora co-founder Jason Sheltzer, Ph.D., in Science Translational Medicine. “Modern cancer drug development is often not mechanism driven, leading to clinical development failures down the line. Meliora is using a novel molecular fingerprint matching method to determine the true mechanism of action of precision cancer therapies,” said David Li, CEO & Co-Founder, Meliora Therapeutics. “By using machine learning to connect MOA with specific therapeutic molecules, we will increase the overall probability of success. We’re thrilled to have the support of this top-tier investor syndicate, and the funds will be used to expand our team and accelerate development of our proprietary computational platform.” "We believe AI will bring revolutionary changes to the drug discovery industry, and are impressed by Meliora's approach to develop a mechanism fingerprint atlas. We are glad to have the opportunity to partner with the amazing team at Meliora,” said Anna Fang, CEO and founding partner at ZhenFund. “Meliora’s computational platform allows companies to identify the true mechanism of action in small molecule compounds, and uncover mischaracterized compounds in the process,” said Jason Sheltzer, Ph.D., Co-Founder, Meliora Therapeutics. “By expanding the therapeutic window of these molecules with known safety profiles, the Meliora team has built a flywheel of precision medicine oncology assets with a higher potential for clinical success by understanding how the drug really works.” “We are excited about Meliora's machine-learning-based approach to mechanism-driven drug discovery. We believe that their novel approach will be a game-changer in the oncology drug development space," said Fady Yacoub, Co-Founder, Managing Partner at HOF Capital. “With better knowledge of a drug’s unique mechanism, scientists can improve drug discovery and increase the success rate of precision therapies in oncology. Additionally companies may also find new vulnerabilities in cancer cells to target or new ways to identify patients who are most likely to respond to a particular targeted therapy. We believe Meliora's novel approach will be highly impactful in the oncology drug development space,” said Michael Polansky, co-founder of Parker Institute for Cancer Immunotherapy and ArsenalBio. Alice Pomponio, Managing Director of BrightEdge, the impact investment arm of the American Cancer Society (ACS) said, “We celebrate the achievements of our ACS grantees and now, through BrightEdge, we are deepening our innovation acceleration capabilities that enable scientific founders like Dr. Jason Sheltzer to translate their research into emerging biotech companies that accelerate ACS’s mission to defeat cancer and advance health equity.” The seed funding will be used to expand Meliora’s computational platform, which includes building a proprietary data moat and selecting mischaracterized scaffolds as strong starting points for its lead precision therapeutic programs. The company has already built a computational prototype which identifies the correct mechanism of action (MOA) for small molecule drugs and generated in-vitro wet lab data for dozens of compounds computationally identified as having an alternate mechanism of action, with many of these compounds generating strong potency against the in silico predicted target. The funding will also be used to expand the team, operations, and build industry partnerships. About Meliora Therapeutics Meliora is reimagining modern cancer drug development by putting genomics and cutting-edge computational approaches as first class principles of product development. The company has developed "molecular fingerprints" for tens of thousands of compounds in order to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (MOA) pairs. This proprietary discovery engine converts the existing world of optimized chemistry into an asset generating flywheel with high potential for clinical success. The company is headquartered in Menlo Park, CA. For more information, visit www.melioratx.com . Contacts

ZhenFund Investments

757 Investments

ZhenFund has made 757 investments. Their latest investment was in Veminsyn as part of their Series A on October 10, 2022.

CBI Logo

ZhenFund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/18/2022

Series A

Veminsyn

$13.88M

No

3

9/29/2022

Seed VC

Meliora Therapeutics

$11M

Yes

4

9/21/2022

Series A

WeView Energy

$56.11M

Yes

2

9/15/2022

Seed VC - II

Subscribe to see more

Subscribe to see more

10

9/12/2022

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

10/18/2022

9/29/2022

9/21/2022

9/15/2022

9/12/2022

Round

Series A

Seed VC

Series A

Seed VC - II

Seed VC

Company

Veminsyn

Meliora Therapeutics

WeView Energy

Subscribe to see more

Subscribe to see more

Amount

$13.88M

$11M

$56.11M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

4

2

10

10

ZhenFund Portfolio Exits

37 Portfolio Exits

ZhenFund has 37 portfolio exits. Their latest portfolio exit was Linkflow on August 09, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/9/2022

Acquired

$99M

6

3/17/2022

IPO

$99M

Public

2

11/14/2021

Acquired

$99M

1

5/7/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

4/23/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/9/2022

3/17/2022

11/14/2021

5/7/2021

4/23/2021

Exit

Acquired

IPO

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

6

2

1

10

10

ZhenFund Fund History

16 Fund Histories

ZhenFund has 16 funds, including Zhen Fund COIX.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/23/2020

Zhen Fund COIX

$4.7M

1

10/8/2019

Zhen Fund COVII

$3.5M

1

7/30/2019

Zhen Fund COV

$18M

1

12/31/2018

Zhen Partners Fund V

Subscribe to see more

Subscribe to see more

10

1/7/2015

Zhen Partners Fund III

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/23/2020

10/8/2019

7/30/2019

12/31/2018

1/7/2015

Fund

Zhen Fund COIX

Zhen Fund COVII

Zhen Fund COV

Zhen Partners Fund V

Zhen Partners Fund III

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$4.7M

$3.5M

$18M

$99M

Sources

1

1

1

10

10

ZhenFund Partners & Customers

2 Partners and customers

ZhenFund has 2 strategic partners and customers. ZhenFund recently partnered with Rocktree Capital on November 11, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

11/26/2019

Partner

United States

1

4/5/2018

Partner

United States, United Kingdom, and China

Subscribe to see more

Subscribe to see more

10

Date

11/26/2019

4/5/2018

Type

Partner

Partner

Business Partner

Country

United States

United States, United Kingdom, and China

News Snippet

Subscribe to see more

Subscribe to see more

Sources

1

10

ZhenFund Team

3 Team Members

ZhenFund has 3 team members, including , .

Name

Work History

Title

Status

Qiang Wang

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Qiang Wang

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.